Cabergoline may act as a radioprotective agent in Cushing's disease.
Kunal ThakkarAnurag LilaVijaya SarathiSwati S JadhavManjunath GoroshiSaba Samad MemonRahul KrishnatryTejpal GuptaRakesh JalaliAtul GoelAbhidha ShahShilpa SankheVirendra PatilTushar R BandgarNalini S ShahPublished in: Clinical endocrinology (2019)
Use of cabergoline in the peri-CRT period did not affect initial remission after CRT but was associated with increased recurrence after initial remission in CD.